Swiss National Bank Buys 500 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Swiss National Bank increased its stake in shares of Arcellx, Inc. (NASDAQ:ACLX) by 0.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 63,400 shares of the company’s stock after purchasing an additional 500 shares during the period. Swiss National Bank owned approximately 0.12% of Arcellx worth $4,862,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. RA Capital Management L.P. boosted its stake in shares of Arcellx by 15.4% in the 3rd quarter. RA Capital Management L.P. now owns 1,851,479 shares of the company’s stock worth $154,617,000 after buying an additional 247,465 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Arcellx during the 4th quarter valued at about $10,016,000. Janus Henderson Group PLC boosted its holdings in shares of Arcellx by 5.7% in the third quarter. Janus Henderson Group PLC now owns 2,011,950 shares of the company’s stock worth $168,026,000 after buying an additional 109,332 shares during the last quarter. Geode Capital Management LLC grew its position in Arcellx by 4.3% during the third quarter. Geode Capital Management LLC now owns 974,967 shares of the company’s stock valued at $81,434,000 after buying an additional 39,781 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its position in Arcellx by 67.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 79,936 shares of the company’s stock worth $6,675,000 after acquiring an additional 32,119 shares during the period. Institutional investors own 96.03% of the company’s stock.

Insider Transactions at Arcellx

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $71.64, for a total transaction of $107,460.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rami Elghandour sold 38,300 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the transaction, the insider now directly owns 149,186 shares in the company, valued at approximately $9,252,515.72. This represents a 20.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,370 shares of company stock worth $4,181,646. 6.24% of the stock is currently owned by company insiders.

Arcellx Trading Up 4.5 %

Shares of ACLX stock opened at $72.48 on Tuesday. The stock’s 50-day moving average price is $66.67 and its 200-day moving average price is $77.85. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -102.08 and a beta of 0.32.

Arcellx (NASDAQ:ACLX) last announced its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The business had revenue of $15.27 million for the quarter, compared to analysts’ expectations of $27.42 million. As a group, research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ACLX. UBS Group boosted their price objective on shares of Arcellx from $106.00 to $114.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Arcellx in a research note on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $115.00 price objective on shares of Arcellx in a research note on Tuesday, December 10th. Finally, Barclays raised shares of Arcellx to a “strong-buy” rating in a report on Friday, November 29th. Thirteen research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $108.46.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).